Active Ingredient(s): Crofelemer
FDA Approved: * December 31, 2012
Pharm Company: * SALIX PHARMS
Category: Gastrointestinal

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Fulyzaq Overview

Crofelemer (USAN, trade name Mytesi) is a botanical drug[1] for the treatment of diarrhea associated with anti-HIV drugs such as nucleoside analog reverse transcriptase inhibitors and protease inhibitors. Other possible uses include diarrhea in children, acute infectious diarrhea, and diarrhea in patients with irritable bowel syndrome.[2] It is a purified oligomeric proanthocyanidin from "dragon's blood", the sap of the South American tree Croton lechleri.&...

Read more Fulyzaq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Crofelemer

Recent Fulyzaq Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet, Delayed Release: 125mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Fulyzaq: (2 results)

Sorted by National Drug Code
  • 65649-802 Fulyzaq 125 mg Enteric Coated Tablet by Salix Pharmaceuticals, Inc.
  • 70564-802 Fulyzaq 125 mg Oral Tablet, Coated by Napo Pharmaceuticals, Inc.

Other drugs which contain Crofelemer or a similar ingredient: (1 result)